Randox Annouces New Lithium Kit to Avoid Toxicity and Optimise Treatment
13 May 2010The new and improved Lithium kit from Randox is intended for the quantitative in vitro determination of Lithium in serum and is suitable for use on a wide range of clinical analysers. Lithium administered as Lithium carbonate is frequently used as a mood stabiliser in the treatment of bipolar disorder (manic depression). It acts by enhancing reuptake of neurotransmitters thereby reducing their concentration in the neuronal junction; the result is a sedating effect on the central nervous system. Due to its narrow therapeutic and toxic range, it is important to monitor lithium levels in the serum to avoid toxicity, optimise therapeutic effect and ensure compliance.
The new reagent is liquid stable for ease of use and offers an improved open vial stability of 14 days at 10oC. Other features include a wide measuring range of 0.281-3.00 mmol/L, excellent precision, traceability to the NIST reference method and limited interference from Bilirubin, Triglycerides and Haemoglobin.
Randox provide a wide range of other tests for monitoring the use of drugs with very small therapeutic ranges. Tests include; Digoxin, Gentamicin, Phenytoin, Theophylline, Valproic acid, Phenobarbital and Carbamazepine.
In addition to this Randox can also provide therapeutic drug quality controls. Our therapeutic drug controls are 100% human in origin and contain a comprehensive menu of 18 analytes with accurately assigned method specific target values and ranges quoted for the most common instruments and methods.